Lys Therapeutics presents new preclinical data in Parkinson’s at the « International Congress of Parkinson’s Disease and Movement Disorders® »



Efficacy and proof-of-concept data of Lys Therapeutics’ monoclonal antibody selected for presentation at the world major congress on Parkinson’s disease, August 27-31, 2023 in Copenhagen, Denmark



Lyon & Caen, France, August 18, 2023 – Lys Therapeutics, a French biotech company pioneering a revolutionary approach to treating patients suffering from neurodegenerative or neurovascular diseases, announced today that it has been selected to present its results at the International Congress of Parkinson’s Disease and Movement Disorders®, to be held in Copenhagen (Denmark) from August 27 to 31, 2023.

In collaboration with the University of Michigan in the United States, Lys Therapeutics will present a poster and its latest advances in Parkinson’s disease research, including results generated with its first-in-class monoclonal antibody (Glunozumab program) in the gold-standard animal model of the disease.


« Glunomab Immunotherapy: A Novel Mechanism Of Action For

The Treatment Of Parkinson’s Disease »

Wednesday, August 30, 2023       1:00 PM – 3:00 PM     Room P36


Lys Therapeutics’ monoclonal antibody and its unique mechanism of action aim to treat neurological diseases by restoring the physiological functioning of the blood-brain barrier (BBB). Specifically, it aims in blood vessels to prevent the binding of a protein overexpressed in patients called tissue plasminogen activator, on endothelial NMDA receptors, an interaction involved in dysregulating BBB permeability.

“We are honored and proud to have been selected to present our work at this major international congress on Parkinson’s disease research. These significant advances were made in collaboration with the teams of Prof. Dan Lawrence of the University of Michigan in the USA, and Prof. Denis Vivien of the Institut du Sang et du Cerveau (BB@C) in France. The use of an antibody to counteract mechanisms involved in blood-brain barrier dysfunction and the associated neuroinflammatory and neurodegenerative processes is particularly promising for slowing-down the progression of this disabling and unfortunately rapidly growing disease,” commented Dr. Manuel Blanc, President and co-founder of Lys Therapeutics.

Earlier in the year, Lys Therapeutics also received financial support from the Michael J. Fox Foundation (MJFF) in the USA to finalize the research on its antibody against Parkinson’s disease and pave the way for a clinical trial.


About Parkinson’s Disease

Parkinson’s disease is a degenerative brain disorder associated with motor symptoms (slow movements, tremors, rigidity and imbalance) and other complications including cognitive, mental health, sleep, pain and sensory problems.

Worldwide, disability and mortality from Parkinson’s disease are increasing faster than any other neurological disorder. The prevalence of the disease has doubled in the last 25 years. According to the World Health Organization (WHO), more than 8.5 million people had Parkinson’s disease in 2019, causing 329,000 deaths. There are approximately 272,500 patients in France, with 25,000 new cases occurring each year. In the United States, there are about 1 million Parkinson’s patients and 60,000 new cases each year. Actor Michael J Fox, himself suffering from Parkinson’s disease, has chosen to dedicate his Foundation to the fight against this disease and to the emergence of new treatments.


About Lys Therapeutics

First-in-class biotherapies against neurological diseases.

Lys Therapeutics is a biotechnology company pioneering a revolutionary approach to treat unmet medical needs in patients suffering from neurovascular or neurodegenerative disorders by targeting blood-brain barrier (BBB) dysfunction.

In the pathophysiology of several neurological diseases, such as ischemic stroke, multiple sclerosis, and Parkinson’s disease, hyperactivation of endothelial NMDA receptors (NMDAr) by overexpressed tissue plasminogen activator (tPA) leads to tight junction degradation and BBB dysfunction, allowing transmigration of inflammatory cells to the brain parenchyma resulting in severe neuroinflammation, a primary cause of neuronal cell death.

Lys Therapeutics’ main drug-candidate is a first-in-class monoclonal antibody displaying a groundbreaking mechanism of action counteracting these mechanisms by specifically preventing inside blood vessels the binding of tPA on NMDAr, without blocking the physiological function of NMDA receptors. By inhibiting this interaction, NMDA receptors can operate normally, haltering downstream deleterious cellular pathways. Tight junctions are reestablished, endothelial cells return to their healthy state and the blood-brain barrier function is restored, protecting the brain from further neuroinflammatory and subsequent neurodegenerative cascades.

Targeting neuroinflammation to tackle neurodegeneration.

More information on